Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Immune checkpoint inhibitors in urothelial bladder cancer

Srikala S. Sridhar, MD, MSc, FRCPC, Princess Margaret Hospital, Toronto, Canada, explores the increased use of immune checkpoint inhibitors across various settings in urothelial bladder cancer. Pembrolizumab has been approved in the post-chemotherapy setting as a result of the KEYNOTE-025 trial (NCT02007070), further research has been conducted within the adjuvant setting in the IMvigor010 (NCT02450331), IMvigor211 (NCT02302807), CheckMate 274 (NCT02632409), and AMBASSADOR (NCT03244384) trials. The KEYNOTE-057 (NCT02625961) additionally investigates pembrolizumab patients with bacille Calmette-Guérin (BCG)-refractory non-muscle invasive bladder cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.


Srikala S. Sridhar, MD, MSc, FRCPC has received consultancy/advisory fees from Merck, Pfizer, Roche, BMS, Bayer, Astra Zeneca, Astellas, Janssen, Seattle Genetics, and Immunomedex.